Physician profile
Rogelio Cantu
NPI 1720020316
$18,520.24
in general payments reported to CMS, 2019-2025
32 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,637 · 2020: $2,069 · 2021: $3,396 · 2022: $2,387 · 2023: $3,016 · 2024: $2,845 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,030.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,081.33 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $1,878.80 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $1,607.05 | 2019-2025 | Tryptyr, Total30, Eysuvis |
| Novartis Pharmaceuticals Corporation | $1,562.32 | 2019-2023 | |
| Abbvie INC. | $1,248.81 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Aerie Pharmaceuticals, INC. | $1,141.64 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $1,073.60 | 2019-2022 | |
| Coopervision INC. | $828.79 | 2020-2025 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $694.28 | 2019-2021 | |
| Biotissue Holdings INC. | $671.10 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $629.56 | 2019-2021 | |
| Allergan, INC. | $616.46 | 2019-2022 | |
| Glaukos Corporation | $516.45 | 2021-2024 | Ce-Marked Kxla System, Idose |
| Johnson & Johnson Surgical Vision, INC. | $494.93 | 2019-2023 | One Series Ultra |
| Shire North American Group INC | $449.58 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $439.49 | 2022-2025 | Vabysmo, Susvimo |
| Dompe US, INC. | $418.23 | 2020-2025 | Oxervate |
| Sight Sciences, INC. | $359.55 | 2019-2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $299.94 | 2021-2025 | Eylea Hd, Eylea |
| Kala Pharmaceuticals, INC. | $272.18 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $234.34 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $187.82 | 2024-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $152.49 | 2022 | |
| Harrow Eye, LLC | $148.46 | 2025 | Vevye |
| Rxsight INC | $144.88 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ani Pharmaceuticals, INC. | $115.39 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $86.32 | 2024 | Tepezza |
| Lombart Brothers, INC. | $60.28 | 2023 | Opd-III |
| Thea Pharma INC. | $42.07 | 2025 | Iyuzeh |
| Astellas Pharma US INC | $35.60 | 2024-2025 | Izervay |
| Tearlab Corp | $15.75 | 2023 | Tearlab Osmolarity System |
| Eyepoint US, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogelio Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.